Healthcare Industry News: amlodipine
News Release - October 26, 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006PALO ALTO, Calif., Oct. 26 (HSMN NewsFeed) -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced that data from three ranolazine-related studies will be presented at the American Heart Association (AHA) Scientific Sessions 2006, which will be held at McCormick Place in Chicago, IL, on November 12 - 15, 2006. The presentations are:
-- Evidence that the antianginal agent, ranolazine, improves post-ischemic stunned myocardium in the rabbit. Monday, November 13, 2006 from 11:30 a.m. to 11:45 a.m. Oral abstract #2171.
-- Exercise capacity on treadmill test predicts future cardiac events. Monday, November 13, 2006 from 2:30 p.m. to 2:45 p.m. Oral abstract #2600.
-- Effects of ranolazine as monotherapy and combination therapy on rate pressure product at rest and during exercise: Results from the MARISA and CARISA trials. Wednesday, November 15, 2006 from 11:30 a.m. to 11:45 a.m. Oral abstract #3362.
Additional information regarding the AHA Scientific Sessions 2006 can be accessed at http://scientificsessions.org .
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, RanexaŽ (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
Source: CV Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.